Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era

Costa, Renata de Oliveira; Neto, Abrahão Hallack; Siqueira, Sheila Aparecida Coelho; Lage, Luís Alberto de Pádua Covas; Paula, Henrique Moura de; Coutinho, Artur Martins; Pereira, Juliana

doi:10.1097/mnm.0000000000000553

Cited by 17 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For one study we extracted the HR from the KM curves with numbers at risk provided by the authors and for six studies we used the KM curves without numbers at risk. For two studies we could not extract the HRs, as there was insufficient data and no Kaplan-Meier curve [ 36 , 48 ].…”

Section: Resultsmentioning

confidence: 99%

“…For two studies we could not extract the HRs, as there was insufficient data and no Kaplan-Meier curve [ 36 , 48 ].…”

Section: Resultsmentioning

confidence: 99%

“…Most articles adjusted for the IPI score [ 34 – 39 , 41 – 43 , 46 ] or age-adjusted IPI [ 44 , 48 , 49 ], some dichotomized the score and others used the individual components. Results were varying widely; in some studies both interim PET and (aa)IPI showed an independent association with PFS or EFS [ 42 , 48 ], others only for interim PET [ 34 , 37 , 39 , 41 , 44 , 53 ], or (aa)IPI [ 43 , 49 ] or no independent associations were found for both interim PET or (aa)IPI [ 35 , 36 , 38 , 46 ]. One could argue that reporting univariate HRs instead of multivariate HRs could result in an overestimation of the predictive value of interim PET.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

Burggraaff

Jong

Hoekstra

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…For two studies we could not extract the HRs, as there was insufficient data and no Kaplan-Meier curve [ 36 , 48 ].…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

Burggraaff

Jong

Hoekstra

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…In a prospective study concerning 111 patients with diffuse large B-cell non-Hodgkin lymphoma, treated with R-CHOP-21 protocols, established a very good prognostic value for patients with negative interim PET (iPET)-computed tomography (CT) after 48 months. Immunohistochemistry was used for categorizing germinal center versus nongerminal center subtypes of diffuse large B-cell non-Hodgkin lymphomas [8]. GLUT-1 and GLUT-3 immunohistological markers were used in another study concerning oral squamous cell carcinoma patients, which showed high FDG uptake in carcinomas with Glut-1 and Glut-3 overexpression [9].…”

Section: Resultsmentioning

confidence: 99%

A review on immunohistochemical and histopathologic validation in PET-CT findings with consideration to microRNAs

Badan

Bonci

Piciu

2019

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

PurposeThis review provides an overview of some of the most recent clinical trials which investigated various types of cancer and other diseases, through the use of PET-CT imaging, highlighting the use of immunohistochemical stains or conventional histopathology for the validation or contradiction of their hypothesis. Furthermore, we investigate a potential new direction of research by analyzing the upcoming role of microRNAs in disease confirmation.MethodsAn extensive search of MEDLINE/PubMed and SCOPUS electronic databases was made, using the MeSH terms “positron emission tomography computed tomography” and “immunohistochemistry” as well as “SUV” and “immunohistochemistry”, restricting the search by clinical trials and time period. Further searches were made for articles regarding Ki-67 and microRNAs in correlation with metabolic PET-CT uptake.ResultsOut of all 389 initial search results, 27 original articles were found relevant to the topic. Their contents were synthesized and discussed regarding the matter at hand. No relevant clinical trials involving microRNAs were found.ConclusionsImmunohistochemical and histopathologic results remain widely used and indispensable in modern research, concerning PET-CT validation. Possible candidates for diagnosis confirmation, in future research, may reside in the further development of microRNAs.

show abstract

“…Compared with the IPI, the NCCN-IPI has enhanced discrimination power for both low- and high-risk patients in the immunochemotherapy era ( 9 ). However, two studies found that NCCN‐IPI high‐risk patients still had quite a high progression-free survival (PFS) rate of 40%–60%, which indicated a need for better classification of high-risk patients ( 10 , 11 ). Since the NCCN-IPI was mainly based on western populations, its stratification values are still challenged by other studies, especially those performed in eastern populations.…”

Section: Introductionmentioning

confidence: 99%

Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study

Xue

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The baseline International Prognostic Index (IPI) is not sufficient for the initial risk stratification of patients with diffuse large B-cell lymphoma (DLBCL) treated with R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). The aims of this study were to evaluate the prognostic relevance of early risk stratification in DLBCL and develop a new stratification system that combines an interim evaluation and IPI. This multicenter retrospective study enrolled 314 newly diagnosed DLBCL patients with baseline and interim evaluations. All patients were treated with R-CHOP or R-CHOP-like regimens as the first-line therapy. Survival differences were evaluated for different risk stratification systems including the IPI, interim evaluation, and the combined system. When stratified by IPI, the high-intermediate and high-risk groups presented overlapping survival curves with no significant differences, and the high-risk group still had >50% of 3-year overall survival (OS). The interim evaluation can also stratify patients into three groups, as 3-year OS and progression-free survival (PFS) rates in patients with stable disease (SD) and progressive disease (PD) were not significantly different. The SD and PD patients had significantly lower 3-year OS and PFS rates than complete remission and partial response patients, but the percentage of these patients was only ~10%. The IPI and interim evaluation combined risk stratification system separated the patients into low-, intermediate-, high-, and very high-risk groups. The 3-year OS rates were 96.4%, 86.7%, 46.4%, and 40%, while the 3-year PFS rates were 87.1%, 71.5%, 42.5%, and 7.2%. The OS comparison between the high-risk group and very high-risk group was marginally significant, and OS and PFS comparisons between any other two groups were significantly different. This combined risk stratification system could be a useful tool for the prognostic prediction of DLBCL patients.

show abstract

Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era

Abstract: Supplemental Digital Content is available in the text.

Cited by 17 publications

References 30 publications

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

A review on immunohistochemical and histopathologic validation in PET-CT findings with consideration to microRNAs

Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study

Contact Info

Product

Resources

About